Neuromyelitis optica relapses: race and rate, immunosuppression and impairment

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment

<p><i>Objective</i> Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabling relapses leading to high morbidity and mortality. Understanding relapse activity and severity is important for treatment decisions and clinical trial design. We assess...

Full description

Bibliographic Details
Main Authors:	Tackley, G, O'Brien, F, Rocha, J, Woodhall, M, Waters, P, Chandratre, S, Halfpenny, C, Hemingway, C, Wassmer, E, Wasiewski, W, Leite, M, Palace, J
Format:	Journal article
Published:	Elsevier 2016

Similar Items

Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders
by: Cheng, F, et al.
Published: (2014)

Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica
by: Sedani, S, et al.
Published: (2012)

Seasonal pattern of variation in neuromyelitis optica relapses
by: Elsone, L, et al.
Published: (2012)

Magnetic resonance imaging in neuromyelitis optica.
by: Tackley, G, et al.
Published: (2014)

Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features.
by: Absoud, M, et al.
Published: (2014)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
by: Waters, P, et al.
Published: (2015)

The in-vivo study of pain in neuromyelitis optica
by: Tackley, G
Published: (2017)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials.
by: Kitley, J, et al.
Published: (2014)

Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
by: Kitley, J, et al.
Published: (2014)

Use of mitoxantrone in neuromyelitis optica.
by: Kitley, J, et al.
Published: (2011)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
by: Palace, J, et al.
Published: (2010)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
by: Waters, P, et al.
Published: (2016)

A practical guide to the treatment of neuromyelitis optica.
by: Palace, J, et al.
Published: (2012)

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
by: Kitley, J, et al.
Published: (2014)

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
by: Kitley, J, et al.
Published: (2014)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
by: Elsone, L, et al.
Published: (2012)

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
by: Kitley, J, et al.
Published: (2012)

The borderland of neuromyelitis optica.
by: Matthews, L, et al.
Published: (2009)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
by: Kitley, J, et al.
Published: (2013)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
by: Viegas, S, et al.
Published: (2009)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
by: Kitley, J, et al.
Published: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
by: Kitley, J, et al.
Published: (2013)

Complement activation in patients with neuromyelitis optica
by: Nytrova, P, et al.
Published: (2014)

Complement activation in patients with neuromyelitis optica.
by: Nytrova, P, et al.
Published: (2014)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
by: Nour, M, et al.
Published: (2014)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
by: Kitley, J, et al.
Published: (2013)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
by: Collongues, N, et al.
Published: (2013)

Myelin-oligodendrocyte glycoprotein antibody-mediated acute inflammatory demyelinating disease mimicking neuromyelitis optica
by: Kitley, J, et al.
Published: (2011)

Treatment of Neuromyelitis Optica: Review and Recommendations.
by: Kimbrough, D, et al.
Published: (2012)

Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica
by: Wilson, R, et al.
Published: (2018)

Treatment of neuromyelitis optica: Review and recommendations
by: Kimbrough, D, et al.
Published: (2012)

NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND
by: Luppe, S, et al.
Published: (2012)

NEUROMYELITIS OPTICA SPECTRUM AND RELATIONSHIP WITH AQUAPORIN-4 ANTIBODY DISEASE: THE OXFORD COHORT
by: Leite, M, et al.
Published: (2009)

The evolving clinical spectrum of neuromyelitis optica
by: Viegas, S, et al.
Published: (2008)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
by: Kim, W, et al.
Published: (2012)

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
by: Mealy, M, et al.
Published: (2014)

MYELIN-OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY AS A CAUSE OF ACUTE DISSEMINATED ENCEPHALOMYELITIS WITH A NEUROMYELITIS OPTICA-LIKE PHENOTYPE IN ADULTS
by: Kitley, J, et al.
Published: (2012)

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
by: Saadoun, S, et al.
Published: (2010)